当前位置:首页 - 行情中心 - 九强生物(300406) - 财务分析 - 现金流量表

九强生物

(300406)

  

流通市值:48.37亿  总市值:66.82亿
流通股本:4.24亿   总股本:5.86亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金741,040,381.5336,831,910.181,592,602,979.541,198,144,986.79
  收到的税费返还0-172,513.55172,513.55
  收到其他与经营活动有关的现金6,941,494.775,189,089.5422,554,276.0610,755,497.18
  经营活动现金流入小计747,981,876.27342,020,999.721,615,329,769.151,209,072,997.52
  购买商品、接受劳务支付的现金145,197,401.8367,502,608.49291,957,694226,254,284.44
  支付给职工以及为职工支付的现金155,994,633.08100,262,384.08317,791,513.75256,568,356.54
  支付的各项税费115,303,391.8646,519,357.94197,849,182.41152,406,070.55
  支付其他与经营活动有关的现金84,690,63332,230,412.45242,621,628.02147,010,714.8
  经营活动现金流出小计501,186,059.77246,514,762.961,050,220,018.18782,239,426.33
  经营活动产生的现金流量净额246,795,816.595,506,236.76565,109,750.97426,833,571.19
二、投资活动产生的现金流量:
  收回投资收到的现金228,000,00050,000,00073,000,00020,000,000
  取得投资收益收到的现金9,872,476.61325,000571,347.27279,736.12
  处置固定资产、无形资产和其他长期资产收回的现金净额48,1805,70061,294153,529
  处置子公司及其他营业单位收到的现金净额0-0-
  收到的其他与投资活动有关的现金0-023,291,611.15
  投资活动现金流入小计237,920,656.6150,330,70073,632,641.2743,724,876.27
  购建固定资产、无形资产和其他长期资产支付的现金10,474,690.789,107,025.6839,240,751.1930,312,420.48
  投资支付的现金80,000,000-459,711,944.67263,000,000
  取得子公司及其他营业单位支付的现金0-0-
  支付其他与投资活动有关的现金0-50,000,000-
  投资活动现金流出小计90,474,690.789,107,025.68548,952,695.86293,312,420.48
  投资活动产生的现金流量净额147,445,965.8341,223,674.32-475,320,054.59-249,587,544.21
三、筹资活动产生的现金流量:
  吸收投资收到的现金0--281,271.5
  其中:子公司吸收少数股东投资收到的现金0--281,271.5
  取得借款收到的现金580,333.9355,177.091,318,001.34998,487.31
  收到其他与筹资活动有关的现金620,845.16-6,171,412.614,888,660.63
  筹资活动现金流入小计1,201,179.06355,177.097,489,413.956,168,419.44
  偿还债务支付的现金471,732.54342,967.74127,419,550.98127,170,792.2
  分配股利、利润或偿付利息支付的现金427,390,757.072,639,404540,152,925.64423,454,639.34
  其中:子公司支付给少数股东的股利、利润2,639,4042,639,4043,011,0643,011,064
  支付其他与筹资活动有关的现金1,547,347.88208,312.220,730,183.6919,863,374.99
  筹资活动现金流出小计429,409,837.493,190,683.94688,302,660.31570,488,806.53
  筹资活动产生的现金流量净额-428,208,658.43-2,835,506.85-680,813,246.36-564,320,387.09
四、汇率变动对现金及现金等价物的影响-412,679.54-194,057.48-389,715.5-164,996.95
五、现金及现金等价物净增加额-34,379,555.64133,700,346.75-591,413,265.48-387,239,357.06
  加:期初现金及现金等价物余额539,645,136.36539,645,136.361,131,058,401.841,131,058,401.84
  期末现金及现金等价物余额505,265,580.72673,345,483.11539,645,136.36743,819,044.78
补充资料:
  净利润210,336,063.58-190,537,287.77-
  资产减值准备19,010,611.25-207,340,661.85-
  固定资产和投资性房地产折旧29,130,300.24-59,779,575.08-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧29,130,300.24-59,779,575.08-
  无形资产摊销6,287,650.64-10,310,634.48-
  长期待摊费用摊销222,433.45-492,048.26-
  处置固定资产、无形资产和其他长期资产的损失350,135.75-2,872,916.43-
  固定资产报废损失156,145.84-830,079.58-
  公允价值变动损失--0-
  财务费用24,767,748.09-49,832,952.55-
  投资损失-7,336,210.85--12,135,601.29-
  递延所得税-8,792,547.62--9,671,517.68-
  其中:递延所得税资产减少-8,306,702.27--8,769,308.6-
    递延所得税负债增加-485,845.35--902,209.08-
  存货的减少-5,977,269.86-20,902,666.99-
  经营性应收项目的减少-33,176,179.27-100,069,630.45-
  经营性应付项目的增加10,861,467.58--57,577,720.62-
  一年内到期的可转换公司债券--8,407,665.78-
  现金的期末余额505,265,580.72-539,645,136.36-
  减:现金的期初余额539,645,136.36-1,042,657,721.31-
  减:现金等价物的期初余额--88,400,680.53-
  现金及现金等价物的净增加额-34,379,555.64--591,413,265.48-
公告日期2026-08-222026-04-272026-04-272025-10-29
审计意见(境内)标准无保留意见
TOP↑